SCHEMBL755566

SCHEMBL755566

COCNC(=O)c1ccoc1Cc1ccc(F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.38
TP53 P04637 1/20 0.38
POLB P06746 3/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 3/20 0.38
NPC1 O15118 1/20 0.38
KMT2A Q03164 4/20 0.37
CYP2C19 P33261 2/20 0.37
PLA2G1B P04054 1/20 0.37
ATG4B Q9Y4P1 1/20 0.37
LIPG Q9Y5X9 1/20 0.37
CYP1A2 P05177 1/20 0.37
LMNA P02545 3/20 0.37
RAB9A P51151 1/20 0.37
TSHR P16473 2/20 0.37
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
MAPT P10636 2/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL765016 0.84 POLB (0.43) L3MBTL1TP53POLBSMN1; SMN2HSD17B10
SCHEMBL758569 0.78 MAOB (0.41) L3MBTL1TP53POLBSMN1; SMN2HSD17B10
SCHEMBL752322 0.76 TP53 (0.47) L3MBTL1TP53POLBSMN1; SMN2HSD17B10
SCHEMBL12206952 0.75 RAB9A (0.38) TP53POLBSMN1; SMN2HSD17B10ALDH1A1
SCHEMBL765461 0.75 MAPT (0.51) POLBHSD17B10ALDH1A1NPC1KMT2A
SCHEMBL6810475 0.74 EGLN1 (0.42) L3MBTL1TP53POLBSMN1; SMN2ALDH1A1
SCHEMBL752081 0.74 CA12 (0.38) L3MBTL1TP53POLBSMN1; SMN2HSD17B10
SCHEMBL16921547 0.74 CA12 (0.38) L3MBTL1TP53POLBSMN1; SMN2HSD17B10
SCHEMBL2486131 0.72 KLKB1 (0.49) L3MBTL1TP53POLBSMN1; SMN2ALDH1A1
SCHEMBL754069 0.70 MMP3 (0.41) POLBSMN1; SMN2ALDH1A1NPC1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170066754-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2017-03-09 US disclosed
US-9572813-B2 Antiviral agent SHIONOGI & CO., LTD. (JP) 2017-02-21 US disclosed
US-20150202208-A1 ANTIVIRAL AGENT SHIONOGI & CO., LTD. (JP) 2015-07-23 US disclosed
EP-1422218-B1 ANTIVIRAL AGENT SHIONOGI & CO (JP) 2012-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150202208-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI L3MBTL1 1368/4885TP53 948/4885POLB 107/4885
US-20170066754-A1 ANTIVIRAL AGENT ZC3HAV1, ZC3HAV1L, CCNI L3MBTL1 1368/4885TP53 948/4885POLB 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.